Reaffirmed: TherapeuticsMD (NYSEMKT:TXMD) Buy Rating Reconfirmed by research analysts Stifel; $14.0 Target in Place

Share

TherapeuticsMD (NYSEMKT:TXMD) Rating Reaffirmed

Analysts at Stifel now has a $14.0 target price on TherapeuticsMD (NYSEMKT:TXMD). Stifel and their recent target price would possibly suggest a potential upside of 114.40% from the company’s previous stock close. The rating has been revealed in a very recent research note on Tuesday, 8 December.

From a total of 5 analysts covering TherapeuticsMD (NYSEMKT:TXMD) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $33 while the lowest target price is $13. The mean of all analyst targets is $19.2 with a 139.18% above today’s ($9.06) stock price. TherapeuticsMD was the topic of 4 analyst reports since September 21, 2015 according to the firm StockzIntelligence Inc. Jefferies maintained shares on December 8 with “Buy” rating.

The stock increased 38.74% or $2.53 on December 9, striking $9.06. Approximately 50 shares of stock traded hands. TherapeuticsMD Inc (NYSEMKT:TXMD) has risen 50.00% since May 6, 2015 and is uptrending. It has outperformed by 50.80% the S&P500.

The overall sentiment of institutions has decreased to 1.22 in Q2 2015. Its down 0.97, from 2.19 in 2015Q2. The ratio worsened, as 17 institutions have sold all the shares of TherapeuticsMD Inc that they owned while 34 funds have taken shares off the table. 14 funds have purchased shares for the first time while 48 added to their positions. These institutions now hold 117.15 million shares or 7.38% more than the 109.10 million shares they owned in 2015Q2.

The Fund Ra Capital Management Llc currently is holding shares equating to 1.28% of its total portfolio in TherapeuticsMD Inc representing a total of 1.52 million shares. Another fund,Morgens Waterfall Vintiadis & Co Inc, is holding a total of 180,000 shares equating to 0.58% of their holdings. Additionally, Gilder Gagnon Howe & Co Llc has a 5.16 million share stake in TherapeuticsMD Inc which represents 0.48% of their total portfolio. The Fund, Stoneridge Investment Partners Llc, based out of Pennsylvania, has also built up a stake in the stock, which represents a total of 0.42% of their total portfolio. Finally Sphera Funds Management Ltd., a fund which is based in the state of Israel reported a total holdings of 512,500 shares.

TherapeuticsMD, Inc. is a women’s health care product company. The company has a market cap of $1.16 billion. The Firm is engaged in creating and commercializing products for women. It currently has negative earnings. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products.

According to Zacks Investment Research, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.” Get a free copy of the Zacks research report on TherapeuticsMD Inc (TXMD).

COMMENTS: